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Abstract
Cdk5/p25 has emerged as a principle therapeutic target for numerous acute and chronic
neurodegenerative diseases, including Alzheimer’s disease. A structure-activity relationship study
of 2,4-diaminothiazole inhibitors revealed that increased Cdk5/p25 inhibitory activity could be
accomplished by incorporating pyridines on the 2-amino group and addition of substituents to the
2- or 3-position of the phenyl ketone moiety. Interpretation of the SAR results for many of the
analogs was aided through in silico docking with Cdk5/p25 and calculating protein hydrations
sites using WaterMap. Finally, improved in vitro mouse microsomal stability was also achieved.
Cyclin-dependent kinase 5 (Cdk5) is a member of the serine/threonine cyclin-dependent
kinase (Cdk) family.1 Many Cdks have emerged as potential therapeutic targets for a variety
of diseases, particularly in oncology.2 Unlike other Cdks that are activated upon binding to
ubiquitously expressed cyclin proteins, Cdk5 activity is predominantly in postmitotic
neurons due to the restricted distribution of its activator protein p35.3 Furthermore,
membrane-associated p35 can be proteolyticly processed by cysteine proteases, such as
calpains, to generate p25 that similarly activates Cdk5 by repositioning the activation loop.4
Even though the catalytic efficiencies of Cdk5/p35 and Cdk5/p25 are similar, it is thought
that the altered subcellular compartmentalization of p25 to the cytosol and nucleus leads to
neuronal toxicity.5
Various neuronal insults can initiate a cascade of events (i.e. increased intracellular [Ca+2]
followed by calpain activation) leading to increased phosphorylation of various protein
substrates, such as tau.6 The hyperphosphorylation of tau (and several other proteins) in
many acute and chronic neurodegenerative diseases has highlighted the potential role of
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Cdk5/p25 in a number of these conditions, especially Alzheimer’s disease.7, 8 In particular,
transgenic animals producing elevated levels of p25 have increased amounts of
phosphorylated tau and demonstrate Alzheimer’s-like neuronal lesions.9 In addition to
Alzheimer’s disease, Cdk5/p25 has been implicated in cerebral ischemia,10 multiple
sclerosis,11 Huntington’s disease,12 Parkinson’s disease13 and amyotrophic lateral sclerosis
(ALS).14 In addition, Cdk5 has been shown to mediate the phosphorylation of PPAR-γ at
specific sites, which leads to insulin resistance. Although the mechanism of Cdk5 activation
in adipocytes is unknown, this study potentially extends the therapeutic scope of Cdk5/p25
inhibition beyond neurological disorder.15
Due to the potential role of Cdk5/p25 in various pathological conditions, considerable
efforts have been expended to identify potent (and ideally selective) inhibitors. A variety of
inhibitor structure classes have been described, including roscovitine (1),16 aloisine-A (2)17
and indirubin-3’-oxime (3),18 which are all ATP-competitive and have also been co-
crystallized with Cdk5/p25.19, 20 Previously, we reported a colorimetric enzyme-linked
immunosorbent assay (ELISA) based high throughput screening protocol for Cdk5 that
utilizes full-length tau as substrate.21 Using this procedure the natural product bellidin (4,
IC50 = 0.2 µM) and the 2,4-diaminothiazole 5 (IC50 = 2.0 µM) were discovered as Cdk5/p25
inhibitors (Figure 1). Both compounds were also co-crystallized with Cdk5/p25 (PDB code:
3O0G) and found to bind at the ATP-site in a similar manner to 1 – 3, except that 5 caused
significant movement of two side chain residues (Asn144 and Lys33) in Cdk5 compared to
the other four inhibitors.22 Herein, we report a structure-activity relationship (SAR) study of
the 2,4-diaminothiazole inhibitors with significant improvement in Cdk5/p25 inhibitory
activity.23, 24
The 2,4-diaminothiazoles were prepared according to the route outlined in Scheme 1.25 An
amine 6 was first allowed to react with thiocarbonyl diimidazole, 7, at room temperature
over 1 h to form the desired isothiocyanate 8, which was generally not isolated. Several
isothiocyanates 8 were commercially available (for example, 3-pyridylisothiocyanate) and
used directly in the next step. 1-Amidino-3,5-dimethylpyrazole nitrate, 9, and DIPEA were
added to the isothiocyanates and the resulting reaction mixture was heated at 50 °C for 2 –
16 h to give 10 in 10 – 60% overall yield. Next, cyclization of 10 in the presence of alpha-
bromoketones in DMF at 50 – 70 °C for 2 – 16 h gave the 2,4-diaminothiazoles 11. In
certain cases where R2 contains Boc-protected amine removal of the protecting group was
achieved by treatment with TFA in DCM at room temperature followed by salt formation
with 4 N HCl in 1,4-dioxane. In addition, intermediate 10 could be treated with MeNH2 in
methanol to generate 12, which was subsequently cyclized to give 11 (R3 = Me), albeit in
only ~ 10% yield. The remaining material was 11 (R3 = H).
Compounds were evaluated for Cdk5/p25 inhibition using a radiometric assay.5, 26 The
goals of the SAR study were to increase potency, to replace the aromatic nitro, to increase in
vitro metabolic stability, and to increase aqueous solubility.
The aromatic nitro in 5 was not necessary for activity. For example, it was initially replaced
with an electron withdrawing fluorine (13) without diminishing activity, whereas
replacement with an electron donating methoxy (14) resulted in reduced activity. In an
attempt to introduce substituents in place of the aniline that would impart increased aqueous
solubility, several piperidines were examined. For example, introduction of a 3- or 4-
piperidine (15 and 16) did not increase potency suggesting that retaining the aryl group may
be optimal. Introduction of amino substituents onto the aryl (17 – 19) resulted in improved
inhibitory activity with IC50 values < 100 nM. However, phenylenediamines raised
oxidative liability concerns. Therefore, the phenyl ring was replaced with a 2-pyridine (20),
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which demonstrated an IC50 of 33 nM and lowered the cLogD7.4 to 3.35 compared to 4.89
for 5.27
Given the results obtained with 20, the substituents on the aryl ketone were more closely
examined. The fluorine could be transposed to the 2-position (21) retaining potent inhibitory
activity, but not the 4-position (22). An electron donating methoxy substituent at the 2-
position (23) only resulted in a slight decrease in activity, but introduction at the 3- or 4-
positions (24 and 25) was much more detrimental. Next, the 2-pyridine was replaced with a
3-pyridine and various substituents on the arylketone were examined. Again 2- and 3-F (26
and 27), but not 4-F (28), resulted in potent inhibition. Removal of the fluorine (29) or
replacement with a 3-nitro (30) was detrimental. Replacement of the fluorine with a
methoxy was only tolerated at the 3-position (31). When the 2-pyridine was replaced with a
4-pyridine, only the 3-F (35) or 2-OMe (37) analogs gave potent inhibition. Interestingly,
replacing the aryl of the ketone with 2-, 3- or 4-pyridine (40 – 42) resulted in significant loss
of activity. Finally, introduction of a methyl onto the thiazole amine (43) abolished
inhibitory activity as might be expected due to the steric clash of the N-methyl group with
the H-bond acceptor carbonyl of GLU81 (Figures 2a and b).28 Disruption of the apparent
internal H-bond between the 4-amino hydrogen and the ketone oxygen would require >8
kcal/mol based on a quantum mechanical coordinate scan.29
During the course of the SAR study it was noted that the analog subset of R1 as 2- or 3-
pyridyl, and the R2 as 2- or 4-substituted phenyl exhibits a trend of the 4-substitued phenyl
analogs being less active compared to the 2-substituents phenyl analogs. In order to probe
these observations further an analysis of the protein hydration sites was conducted. The
compounds in Table 1 were docked using Glide30a in XP mode with a core constraint based
on the crystallized analog 5. Using WaterMap30b, c to calculate the protein hydration sites
in the vicinity of the ATP binding pocket reveals site 16 as having a stable ΔG = −3.2 kcal/
mol as shown in Figure 3. In contrast, site 48 has an unstable ΔG = 6.2 kcal/mol.
Using the listed activities, a binding ΔΔG = −2.6 kcal/mol was calculated for the exemplar
pair of 26 and 28. Both ligands displace site 48 and the unlabeled sites with a favorable
effect on binding affinity. In addition, the 4-fluorophenyl of 28 also displaces site 16. The
displacement of a stable hydration site results in a predicted ΔΔG in agreement with the
observed value within experimental and computational error. Similar ΔΔG values were
observed for the other ortho/para pairs in the subset. For compounds in Table 1 where R2 is
4-pyridyl and for 15 – 19 the SAR is possibly due to a different binding orientation. Further
studies will be necessary to address this possibility.
The selectivity of 26 was briefly examined against Cdk2 and GSK-3β two structurally
related serine/threonine kinases belonging to the CMGC kinase subgroup. Compound 26
displayed potent activity against both kinases with IC50 values of 25 nM and 45 nM ([ATP]
= 60 µM) for Cdk2 and GSK-3β, respectively.
Next, the inhibitory effect of 26 was studied in primary neurons. Rat brain cells were
incubated with compound at five different concentrations for 4 h at 37 °C, lysed and
immunoblotted with antibodies against Cdk5 and phosphorylated tau at Serine 235
(Ptau235), a predominant phosphorylation site.31 Roscovitine, 1, was used as a positive
control. As shown in Figure 4, 26 displayed a dose-dependent inhibition of tau
phosphorylation with an EC50 value of 5.5 µM.
In vitro mouse microsomal stability of 26 was also assessed at 10 µM and a t1/2 = 29 min
was determined. Based on computational models predicting the intrinsic oxidative stability
to CYP450 3A4 and 2D6, the 2-position of the pyridine was predicted to be a site of
oxidation. Since this area of the molecule is also predicted not to make close contacts with
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Cdk5 when bound, assuming a similar binding mode as 5, an increase in metabolic stability
was anticipated with additional of a trifluoromethyl at this position (44). Although the Cdk5
inhibitory IC50 increased to 160 nM the mouse microsomal half-life increased to 66 min.
In summary, a series of potent 2,4-diaminothiazoles were designed and synthesized based
upon the previously identified Cdk5/25 inhibitor 5. Incorporation of pyridines in place of the
4-chlorophenyl and addition of substituents to the 2- or 3-position of the phenyl ketone
moiety resulted in increased inhibitory potency, such as 26 (LDN-193594). Interpretation of
the SAR results for many of the analogs was aided through in silico docking with Cdk5/p25
and calculating protein hydrations sites with WaterMap.30b, c Furthermore, addition of a
substituent at the 2-position of the incorporated 3-pyridine resulted in increased in vitro
mouse microsomal stability. The results of this study provide probes to study Cdk5/p25-
mediated biology and should prove useful in the further optimization of this series of Cdk5
inhibitors.
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Examples of Cdk5/p25 inhibitors.
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2a. A view of Cdk5/p25 complexed with 5 (in CPK rendering with green C, red O, dark
green Cl, blue N and yellow S). Cdk5 is shown with white ribbons and p25 in yellow
ribbons with 5 occupying the ATP binding site.
2b. A close view of 5 (ball and stick rendering) showing the H-bonds (yellow dashed lines)
to the hinge residues in Cdk5 and of the NO2 group with the catalytic Lys33.
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A view showing 26 (brown carbons) and 28 (green carbons) docked into the Cdk5/p25
binding site. The spheres represent protein hydration sites as computed by WaterMap with a
ΔG: −3.2 (bright green) to 6.2 kcal/mol (bright red). Only overlapped sites are shown for
clarity.
Laha et al. Page 9














The inhibition effect of 26 on tau phosphrylation in primary neurons. Western blot is
presented where tau phosphorylation was probed by antibody Ptau235 and Cdk5 was used as
the control. Relative band intensity is shown in the bar graph. Roscovitine, 1, at 30 µM was
used as a positive control.
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General synthetic approach to 2,4-diaminothiazoles. (a) DIPEA, DMF, rt, 1–6 h; (b) 1-
amidino-3,5-dimethylpyrazole•HNO3 (9), DIPEA or KOH, DMF, 50 °C, 2–16 h; (c)
R2C(=O)CH2Br, TEA or DIPEA, DMF, 50 °C -70 °C, 2–16 h; (d) TFA, DCM, rt and then
4N HCl in 1,4-dioxane; (e) MeNH2, MeOH, rt.
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Table 1
Cdk5/p25 inhibitory result for 5 and 13 – 44.
compound R1 R2 R3 IC50, nM
5 4-ClPh 3-NO2Ph H 750
13 4-ClPh 3-FPh H 700
14 4-ClPh 3-OMePh H 4000
15 3-Piperidyl 3-FPh H 500
16 4-Piperidyl 3-FPh H 6200
17 3-NH2Ph 3-FPh H 31
18 3-NHMePh 3-FPh H 44
19 4-NMe2Ph 3-FPh H 68
20 2-Py 3-FPh H 33
21 2-Py 2-FPh H 38
22 2-Py 4-FPh H 1200
23 2-Py 2-OMePh H 80
24 2-Py 3-OMePh H 400
25 2-Py 4-OMePh H 1100
26 3-Py 2-FPh H 30
27 3-Py 3-FPh H 62
28 3-Py 4-FPh H 4100
29 3-Py Ph H 341
30 3-Py 3-NO2Ph H 130
31 3-Py 2-OMePh H 418
32 3-Py 3-OMePh H 11
33 3-Py 4-OMePh H 3500
34 4-Py 2-FPh H 360
35 4-Py 3-FPh H 18
36 4-Py 4-FPh H 400
37 4-Py 2-OMePh H 60
38 4-Py 3-OMePh H 200
39 4-Py 4-OMePh H 600
40 3-Py 2-Py H 800
41 3-Py 3-Py H 100
42 3-Py 4-Py H 1710
43 3-Py 2-FPh Me > 10000
44 3-(6-CF3)Py 2-FPh H 160
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